We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos Featured in Leading Drug Discovery Journal
News

Galapagos Featured in Leading Drug Discovery Journal

Galapagos Featured in Leading Drug Discovery Journal
News

Galapagos Featured in Leading Drug Discovery Journal

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos Featured in Leading Drug Discovery Journal "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV has announced that an article presenting the Company's approach to target discovery will appear in the October 15, 2005 issue of Drug Discovery.

The paper, entitled “Biology calls the targets: combining RNAi and disease biology”, gives insight into how Galapagos applies its proprietary RNA interference technology.

Furthermore, the article explains how this biology-driven approach can be used to functionally validate drug targets for major human diseases.

“Galapagos has built extensive expertise in using RNAi to discover and validate novel drug targets in a wide range of disease areas,” said Onno van de Stolpe, CEO of Galapagos.

“Our scientists were invited to present our protein knock-down technology using adenovirus-based RNAi libraries to discover new targets in human primary cells.”

“There is particularly strong interest in RNAi in the pharmaceutical industry and we believe targets identified using our approach could improve overall success rates in the drug discovery process.”

“The confidence is underscored by the fact that our pharmaceutical partners have taken targets identified using this biology-driven strategy, forward into their internal drug discovery programs.”

Advertisement